GAL-INT-6 The safety and efficacy of galantamine in patients with Vascular dementia or AD with cerebrovascular disease Sean Lilienfeld MD, FCP, MMed Janssen Research Foundation

3/16/01


Click here to start


Table of Contents

GAL-INT-6 The safety and efficacy of galantamine in patients with Vascular dementia or AD with cerebrovascular disease Sean Lilienfeld MD, FCP, MMed Janssen Research Foundation

Interactions between vascular dementia and Alzheimer’s disease

Reminyl in vascular and mixed dementia: trial inclusion criteria

Inclusion Criteria Probable Vascular Dementia (NINDS-AIREN)

Inclusion Criteria Probable Vascular Dementia (NINDS-AIREN)

Inclusion Criteria Probable Vascular Dementia (NINDS-AIREN)

Inclusion Criteria Mixed Dementia (Possible AD with CVD)

Inclusion Criteria Mixed Dementia (Possible AD with CVD)

Exclusion Criteria

NINDS-AIREN Radiology

Patient characteristics

ADAS-cog Scores: Placebo patients Over 6 Months

ADAS-cog Scores: Placebo patients Over 6 Months

NPI Scores: Placebo patients Over 6 Months

NPI Scores: Placebo patients Over 6 Months

DAD Scores: Placebo patients Over 6 Months

DAD Scores: Placebo patients Over 6 Months

Efficacy results

Conclusions

Conclusions

Galantamine Significantly Improved Both Primary Endpoints and Both Secondary Endpoints

Author: Excerpta Medica